Expertise in
7
conditions

Emmanuel Morelon

Unité De Formation Et De Recherche Lyon Est, 
EE 
Expertise in
7
conditions
Unité De Formation Et De Recherche Lyon Est, 
EE 

Overview

Emmanuel Morelon practices practicing medicine in Estonia.

Mr. Morelon is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Kidney Disease, Cardiac Arrest, Squamous Cell Skin Carcinoma, Kidney Transplant, and Pancreas Transplant.

He is actively involved in clinical research, co-authoring 206 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Unité De Formation Et De Recherche Lyon Est, Estonia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
Enrollment Status: Completed
Publish Date: July 27, 2026
Intervention Type: Drug
Study Phase: Phase 4
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T
Enrollment Status: Completed
Publish Date: May 12, 2026
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study
Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Other, Drug
Study Drug: Corticosteroid boluses Methylprednisolone
Study Phase: Phase 3
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Enrollment Status: Terminated
Publish Date: July 23, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 3
Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure
Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure
Enrollment Status: Completed
Publish Date: November 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
Health Economic Analysis of Islet Cell Transplantation for Patients With Severe Forms of Brittle Type 1 Diabetes
Health Economic Analysis of Islet Cell Transplantation for Patients With Severe Forms of Brittle Type 1 Diabetes
Enrollment Status: Unknown
Publish Date: June 24, 2022
Intervention Type: Drug, Procedure
Study Drug: Best Medical Care
Study Phase: Phase 3
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Other
Study Phase: Not Applicable
Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function.
Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function.
Enrollment Status: Terminated
Publish Date: November 21, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

206 Total Publications

Donor-specific antibodies in vascularized composite allotransplantation: A multicenter study.
Donor-specific antibodies in vascularized composite allotransplantation: A multicenter study.
Journal: Transplant immunology
Published: June 05, 2026

Frequently Asked Questions about Emmanuel Morelon

Is Emmanuel Morelon a top-rated expert for Kidney Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Emmanuel Morelon is classified as an Elite expert for Kidney Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emmanuel Morelon participate in research or clinical trials?

Yes. Emmanuel Morelon has published 206 articles and abstracts on conditions like Kidney Transplant. You can view a list of Emmanuel Morelon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Morelon's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile